Publication Number
WO/2023/027671
Publication Date
02.03.2023
International Application No.
PCT/TR2022/050885
International Filing Date
22.08.2022
Title
[English]
A SOLID PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
[French]
COMPOSITION PHARMACEUTIQUE SOLIDE COMPRENANT DU SACUBITRIL ET DU VALSARTAN
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
Inventors **
KARABULUT, Serif
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
ERDOGAN, Akif
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
ATAK, Fadime Bilgehan
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
SUNEL, Fatih
Istınye Mahallesı Balabandere Caddesı No:14
34460 Sarıyer/Istanbul, TR
Priority Data
2021/013354
24.08.2021
TR
Application details
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Abstract
[English]
The present invention relates to a solid pharmaceutical composition comprises sacubitril in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph thereof and valsartan in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph thereof and at least one pharmaceutically acceptable excipient wherein the amount of binder is 0.1% to 20.0% by weight of the total composition. Further, the present invention also relates
[French]
La présente invention concerne une composition pharmaceutique solide comprenant du sacubitril sous la forme de la base libre ou sous la forme de sels pharmaceutiquement acceptables, un polymorphe cristallin correspondant et du valsartan sous la forme de la base libre ou sous la forme de sels pharmaceutiquement acceptables, un polymorphe cristallin correspondant et au moins un excipient pharmaceutiquement acceptable, la quantité de liant étant de 0,1 % à 20,0 % en poids de la composition totale. En outre, la présente invention concerne également un procédé.